Business context and reporting period
Gain Therapeutics, Inc. filed this unaudited Form 10-Q for the quarter and nine months ended September 30, 2022. The company is a preclinical-stage biotechnology business developing small-molecule therapeutics using its in-licensed SEE-Tx platform. It has no approved products and has generated no product-sale revenue.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Total revenue | $0 | $27,345 | $140,108 | $121,786 |
| Research and development expense | $1.965 million | $2.477 million | $6.103 million | $5.692 million |
| General and administrative expense | $2.786 million | $2.187 million | $7.253 million | $5.047 million |
| Net loss | $4.558 million | $4.664 million | $12.916 million | $10.671 million |
| Basic and diluted loss per share | $0.38 | $0.39 | $1.09 | $1.11 |
At September 30, 2022, cash and cash equivalents were $10.880 million and marketable securities were $14.767 million, or $25.647 million combined. Current assets were $24.349 million and current liabilities $4.332 million, implying working capital of approximately $20.017 million. Total liabilities were $5.663 million; debt was approximately $585,000. The company reported an accumulated deficit of $33.842 million.
For the nine months, operating cash use was $10.788 million, investing cash use was $14.909 million (primarily purchases of marketable securities), and financing cash use was $57,000. Cash, cash equivalents and restricted cash declined by $26.003 million to $10.909 million. Profit margins are not meaningful given the absence of product sales and continuing operating losses.
Material changes versus the prior comparable period
- Q3 net loss narrowed by about $105,000 year over year, despite no revenue in Q3 2022 versus $27,345 in Q3 2021. Higher interest income and a favorable foreign-exchange result helped offset operating loss.
- Nine-month net loss widened by $2.246 million. R&D expense rose $412,000, mainly due to personnel costs and stock-based compensation, partly offset by lower external services. G&A expense rose $2.205 million, reflecting higher corporate, legal, insurance, professional-service, personnel and stock-compensation costs.
- Cash, cash equivalents and marketable securities fell from $36.881 million at December 31, 2021 to $25.647 million at September 30, 2022. The company invested $15.804 million in U.S. Treasury securities during the nine months; those securities had a $98,000 unrealized loss, attributed primarily to interest-rate movements, with no credit-loss allowance recorded.
- Outstanding common shares remained 11,883,368 at September 30, 2022. The company had an effective shelf registration statement for up to $100 million and an at-the-market sales prospectus for up to $16 million; it reported no sales under either as of quarter-end.
Outlook, commentary, risks and unusual items
- Management said existing cash, cash equivalents and marketable securities were expected to fund operating and capital requirements into Q2 2024. This estimate depends on assumptions that may prove inaccurate; the company expects further losses and may need additional financing.
- The company is prioritizing Parkinson’s and Gaucher disease programs, continuing Krabbe disease work, and pursuing oncology programs and non-dilutive funding. Management anticipated completing IND-enabling toxicology studies for lead candidate GT-02287 in Q1 2023, with a goal of filing for a Phase 1 first-in-human study in Australia in mid-2023. These are plans, not assured milestones.
- Management described preclinical evidence for GT-02287 in GBA1 Parkinson’s disease models, but the filing emphasizes that preclinical results may not predict human outcomes. The company disclosed that it had not tested product candidates in clinical trials and that further preclinical, clinical, regulatory and manufacturing work is required.
- Key risks include clinical and regulatory failure or delay, difficulty enrolling patients for rare diseases, dependence on third parties and the SEE-Tx license, financing availability and dilution, competition, intellectual-property risks, COVID-19 and macroeconomic or supply-chain disruption.
- Disclosure controls and procedures were deemed ineffective at September 30, 2022 because a material weakness in financial-statement preparation and review controls had not been fully remediated. The previously identified weakness concerning qualified accounting personnel was reported as remediated; the company said it needed more time to demonstrate the remaining remediation was effective.
- The company reported no material legal proceedings. It had $1.176 million in research commitments at September 30, 2022. Other notable items included $967,742 of stock-based compensation for the nine months and the early extinguishment, without fees or charges, of a small Swiss government loan in February 2022.
Important facts for investors to verify
- Whether the stated cash runway into Q2 2024 remains achievable, and what operating-spend assumptions underpin it.
- Progress and timing of GT-02287 toxicology work, regulatory submissions and the planned Australian Phase 1 trial.
- Whether additional funding, partnering or use of the shelf/ATM will be needed, and the potential dilution or rights granted.
- Whether the remaining material weakness in financial reporting controls is remediated and operating effectively.
- How R&D and G&A spending, commitments and cash burn develop as programs advance.